WO2012130720A3 - PREDICTION OF RESPONSIVENESS TO PIK3/mTOR INHIBITORS - Google Patents
PREDICTION OF RESPONSIVENESS TO PIK3/mTOR INHIBITORS Download PDFInfo
- Publication number
- WO2012130720A3 WO2012130720A3 PCT/EP2012/055097 EP2012055097W WO2012130720A3 WO 2012130720 A3 WO2012130720 A3 WO 2012130720A3 EP 2012055097 W EP2012055097 W EP 2012055097W WO 2012130720 A3 WO2012130720 A3 WO 2012130720A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- inhibitor
- treatment
- responsiveness
- pi3k
- pik3
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A method for determining the responsiveness of a mammalian tumor cell to treatment with an inhibitor of the phosphoinosite 3-kinase (PI3K) and/or mammalian target of rapamycin (mTOR) pathway, said method comprising determining the c-MYC and/or NOTCH1 level in said tumor cell, wherein said level is indicative of whether the cell is likely to respond or is responsive to the treatment. It further refers to an in vitro method for the identification of a resistance to treatment or of predicting or monitoring the efficacy of treatment, of solid tumor cancer with an inhibitor of the PI3K and/or mTOR pathway in a patient suffering from said cancer. It further refers to a combination comprising an amount of an inhibitor of the PI3K and/or mTOR pathway, and an amount of a c-MYC and/or NOTCH 1 inhibitor.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161468418P | 2011-03-28 | 2011-03-28 | |
EP11160039.1 | 2011-03-28 | ||
EP11160039 | 2011-03-28 | ||
US61/468,418 | 2011-03-28 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2012130720A2 WO2012130720A2 (en) | 2012-10-04 |
WO2012130720A3 true WO2012130720A3 (en) | 2012-12-20 |
Family
ID=44343936
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2012/055097 WO2012130720A2 (en) | 2011-03-28 | 2012-03-22 | PREDICTION OF RESPONSIVENESS TO PIK3/mTOR INHIBITORS |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2012130720A2 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013138585A1 (en) | 2012-03-16 | 2013-09-19 | The Broad Institute, Inc. | Multiplex methods to assay mixed cell populations simultaneously |
EP3105353A4 (en) | 2014-02-12 | 2017-11-01 | Dana-Farber Cancer Institute, Inc. | P13k-mtorc1-s6k1 signaling pathway biomarkers predictive of anti-cancer responses |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006122053A2 (en) * | 2005-05-09 | 2006-11-16 | Ariad Gene Therapeutics, Inc. | Biomarkers for evaluating likelihood of tumor sensitivity to an mtor inhibitor |
WO2009039457A1 (en) * | 2007-09-19 | 2009-03-26 | The Trustees Of Boston University | Identification of novel pathways for drug development for lung disease |
WO2009103790A2 (en) * | 2008-02-21 | 2009-08-27 | Universite Libre De Bruxelles | Method and kit for the detection of genes associated with pik3ca mutation and involved in pi3k/akt pathway activation in the er-positive and her2-positive subtypes with clinical implications |
WO2010030865A2 (en) * | 2008-09-11 | 2010-03-18 | The Regents Of The University Of California | Loss of fbxw7 is a biomarker of sensitivity to treatment of tumors with inhibitors of mtor |
WO2010040124A1 (en) * | 2008-10-03 | 2010-04-08 | Dana-Farber Cancer Institute, Inc. | Compositions, kits and methods for the diagnosis, prognosis, and monitoring of cancer using golph3 |
-
2012
- 2012-03-22 WO PCT/EP2012/055097 patent/WO2012130720A2/en active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006122053A2 (en) * | 2005-05-09 | 2006-11-16 | Ariad Gene Therapeutics, Inc. | Biomarkers for evaluating likelihood of tumor sensitivity to an mtor inhibitor |
WO2009039457A1 (en) * | 2007-09-19 | 2009-03-26 | The Trustees Of Boston University | Identification of novel pathways for drug development for lung disease |
WO2009103790A2 (en) * | 2008-02-21 | 2009-08-27 | Universite Libre De Bruxelles | Method and kit for the detection of genes associated with pik3ca mutation and involved in pi3k/akt pathway activation in the er-positive and her2-positive subtypes with clinical implications |
WO2010030865A2 (en) * | 2008-09-11 | 2010-03-18 | The Regents Of The University Of California | Loss of fbxw7 is a biomarker of sensitivity to treatment of tumors with inhibitors of mtor |
WO2010040124A1 (en) * | 2008-10-03 | 2010-04-08 | Dana-Farber Cancer Institute, Inc. | Compositions, kits and methods for the diagnosis, prognosis, and monitoring of cancer using golph3 |
Also Published As
Publication number | Publication date |
---|---|
WO2012130720A2 (en) | 2012-10-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2012148540A8 (en) | Combination of kinase inhibitors and uses thereof | |
WO2013009655A3 (en) | Uses of labeled hsp90 inhibitors | |
WO2008127718A3 (en) | Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors | |
WO2011135459A3 (en) | Methods and devices for predicting treatment efficacy | |
WO2008138578A3 (en) | Methods, kits, and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy | |
IL197450A0 (en) | Biomarkers of target modulation, efficacy, diagnosis and/or prognosis for raf inhibitors | |
NZ608459A (en) | Molecular diagnostic test for cancer | |
NZ617003A (en) | Method to use gene expression to determine likelihood of clinical outcome of renal cancer | |
WO2009045389A3 (en) | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors | |
WO2008115419A3 (en) | Gene expression markers for prediction of patient response to chemotherapy | |
WO2006101925A3 (en) | Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors | |
WO2013093635A3 (en) | Plasma micrornas for the detection of early colorectal cancer | |
WO2012006589A3 (en) | Methods and compositions for identification, assessment and treatment of cancers associated with hedgehog signaling | |
EA201390149A1 (en) | METHODS FOR DETECTING DISEASES OR PATHOLOGICAL CONDITIONS USING PHAGOCYTARY CELLS | |
WO2011109584A3 (en) | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors | |
EP4303584A3 (en) | Methods for detecting signatures of disease or conditions in bodily fluids | |
NZ597655A (en) | Method for predicting efficacy of drugs in a patient | |
WO2011133477A3 (en) | Compositions and methods for prediction of drug sensitivity, resistance, and disease progression | |
WO2011088137A3 (en) | Bad pathway gene signature | |
WO2013083098A3 (en) | Method of determination of cancer cell drug sensitivity towards aurora kinase inhibitors | |
WO2011047033A3 (en) | Biomarker for identification of melanoma tumor cells | |
WO2013071163A3 (en) | Biomarkers of response to proteasome inhibitors | |
WO2012079059A3 (en) | Post-treatment breast cancer prognosis | |
MX2012003997A (en) | Biomarkers for predicting the sensitivity and response of protein kinase ck2-mediated diseases to ck2 inhibitors. | |
WO2012019000A3 (en) | Biomarkers for the identification monitoring and treatment of ovarian cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12724578 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 12724578 Country of ref document: EP Kind code of ref document: A2 |